aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.15372/ATER20180204ateroskleroz-71Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESСООТНОШЕНИЕ ХОЛЕСТЕРИНА ЛИПОПРОТЕИДОВ НИЗКОЙ ПЛОТНОСТИ К АПОЛИПОПРОТЕИДУ-В КАК МАРКЕР РАЗМЕРА ЧАСТИЦ ЛИПОПРОТЕИДОВ НИЗКОЙ ПЛОТНОСТИThe ratio of low-density lipoprotein cholesterol to apolipoprotein-B as a marker of low-density lipoprotein particle sizeКаневаА. М.KanevaA. M.amkaneva@mail.ruПотолицынаН. Н.PotolitsynaN. N.potol_nata@list.ruБойкоЕ. Р.BojkoE. R.boiko60@inbox.ruИнститут физиологии Коми научного центра УрО РАН, ФИЦ Коми НЦ УрО РАНInstitute of Physiology of Komi Science Center of the Ural Branch of the Russian Academy of Sciences, FRC Komi SC UB RAS2018270920191422531Copyright © Канева А.М., Потолицына Н.Н., Бойко Е.Р., 20192019Канева А.М., Потолицына Н.Н., Бойко Е.Р.Kaneva A.M., Potolitsyna N.N., Bojko E.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/71

Цель работы - определить информативность и клиническую значимость соотношения холестерина липопротеидов низкой плотности к аполипопротеиду-В (ХС ЛПНП/апоВ) при оценке атерогенности липидного профиля крови человека. Материал и методы. Обследованы 157 практически здоровых мужчин с нормолипидемией. Содержание общего холестерина, триглицеридов, холестерина липопротеидов высокой плотности (ХС ЛПВП), апоА-I, апоВ и апоЕ в плазме крови измеряли на сканирующем спектрофотометре Powerwave 200 (США) с использованием коммерческих наборов (Chronolab Systems, Spain). Проводили вычисление расчетных показателей и индексов липидного обмена. Результаты. При расчете соотношения ХС ЛПНП/апоВ установлена предпочтительность использования вместо показателей общего уровня апобелка значений содержания апоВ, входящего непосредственно в состав липопротеидов низкой плотности (ЛПНП). Выявлено, что низкие значения соотношения ХС ЛПНП/апоВ ЛПНП, указывающие на преобладание в крови маленьких, плотных частиц ЛПНП, ассоциированы с высокими уровнями триглицеридов и пониженным содержанием апоЕ. На основании полученных данных можно заключить, что апоЕ, являясь метаболически активным апобелком и регулируя время нахождения в крови триглицерид-богатых липопротеидов, оказывает влияние на размер частиц ЛПНП. Заключение. Наличие маленьких, плотных частиц ЛПНП в крови здоровых людей может быть следствием нарушения катаболизма и метаболических превращений липопротеидов.

The aim of this study was to determine the informative value and clinical significance of the ratio of low-density lipoprotein cholesterol to apolipoprotein-B (LDL-C/apoB) in the overall evaluation of blood lipid profile atherogenicity. Material and methods. A total of 157 apparently healthy men with normolipidemia were included in the study. The plasma levels of total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), apoA-I, apoB and apoE were measured on the Powerwave 200 automated spectrophotometer (USA) with commercially available kits (Chronolab Systems, Spain). Several clinical ratios and indices of lipid metabolism were calculated. Results. The use of apoB content in low-density lipoproteins (LDL) instead of total apoB level in plasma is preferable in calculating the LDL-C/apoB ratio. Low values of the LDL-C/LDL-apoB ratio, indicating a predominance of small dense LDL particles in plasma, were associated with higher triglycerides levels and lower apoE levels. This finding indicates that apoE, being a metabolically active apolipoprotein and regulating residence of triglycerides-rich lipoproteins in plasma, can affect size of the LDL particles. Conclusion. Thus, presence of small, dense LDL particles in plasma of men with normolipidemia can be a consequence of disturbances in catabolism and metabolic turnover of lipoproteins.

липидный обменлипопротеиды низкой плотностиаполипопротеидыатерогенностьlipid metabolismlow-density lipoproteinsapolipoproteinsatherogenicityReferencesRajman I., Maxwell S., Cramb R., Kendall M. Particle size: the key to the atherogenic lipoprotein? // QJM. 1994. Vol. 87, N 12. P. 709-720.Rajman I., Maxwell S., Cramb R., Kendall M. Particle size: the key to the atherogenic lipoprotein? // QJM. 1994. Vol. 87, N 12. P. 709-720.Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein // Biochem. Soc. Trans. 2003. Vol. 31, N 5. P. 1066-1069.Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein // Biochem. Soc. Trans. 2003. Vol. 31, N 5. P. 1066-1069.Arai H., Kokubo Y., Watanabe M. et al. Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study // J. Atheroscler. Thromb. 2013. Vol. 20, N 2. P. 195-203.Arai H., Kokubo Y., Watanabe M. et al. Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study // J. Atheroscler. Thromb. 2013. Vol. 20, N 2. P. 195-203.Wägner A.M., Jorba O., Rigla M. et al. LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes // Acta Diabetol. 2002. Vol. 39, N 4. P. 215-220.Wägner A.M., Jorba O., Rigla M. et al. LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes // Acta Diabetol. 2002. Vol. 39, N 4. P. 215-220.Gazi I.F., Tsimihodimos V., Tselepis A.D. et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles // Expert Opin. Biol. Ther. 2007. Vol. 7, N 1. P. 53-72.Gazi I.F., Tsimihodimos V., Tselepis A.D. et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles // Expert Opin. Biol. Ther. 2007. Vol. 7, N 1. P. 53-72.Hirano T., Ito Y., Yoshino G. Measurement of small dense low-density lipoprotein particles // J. Atheroscler. Thromb. 2005. Vol. 12, N 2. P. 67-72.Hirano T., Ito Y., Yoshino G. Measurement of small dense low-density lipoprotein particles // J. Atheroscler. Thromb. 2005. Vol. 12, N 2. P. 67-72.Hattori Y., Suzuki M., Tsushima M. et al. Development of approximate formula for LDL-chol, LDL-apo B and LDL-chol/LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL // Atherosclerosis. 1998. Vol. 138, N 2. P. 289-299.Hattori Y., Suzuki M., Tsushima M. et al. Development of approximate formula for LDL-chol, LDL-apo B and LDL-chol/LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL // Atherosclerosis. 1998. Vol. 138, N 2. P. 289-299.Furuya D., Yagihashi A., Nasu S. et al. LDL particle size by gradient-gel electrophoresis cannot be estimated by LDL-cholesterol/apolipoprotein B ratios // Clin. Chem. 2000. Vol. 46, N 8. P. 1202-1203.Furuya D., Yagihashi A., Nasu S. et al. LDL particle size by gradient-gel electrophoresis cannot be estimated by LDL-cholesterol/apolipoprotein B ratios // Clin. Chem. 2000. Vol. 46, N 8. P. 1202-1203.Décary S., Dumont G., Lamarche B. et al. Assessment of the validity of the frequently used lipid indices for predicting LDL peak particle diameter in a large cohort of 1955 normal and dyslipidemic subjects // Clin. Biochem. 2010. Vol. 43, N 4-5. P. 401-406.Décary S., Dumont G., Lamarche B. et al. Assessment of the validity of the frequently used lipid indices for predicting LDL peak particle diameter in a large cohort of 1955 normal and dyslipidemic subjects // Clin. Biochem. 2010. Vol. 43, N 4-5. P. 401-406.Dobiasova M., Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)) // Clin. Biochem. 2001. Vol. 34, N 7. P. 583-588.Dobiasova M., Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)) // Clin. Biochem. 2001. Vol. 34, N 7. P. 583-588.Sniderman A.D., Tremblay A.J., de Graaf J., Couture P. Calculation of LDL apoB // Atherosclerosis. 2014. Vol. 234, N 2. P. 373-376.Sniderman A.D., Tremblay A.J., de Graaf J., Couture P. Calculation of LDL apoB // Atherosclerosis. 2014. Vol. 234, N 2. P. 373-376.Morita S.Y. Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis // Biol. Pharm. Bull. 2016. Vol. 39, N 1. P. 1-24.Morita S.Y. Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis // Biol. Pharm. Bull. 2016. Vol. 39, N 1. P. 1-24.Sniderman A.D., Kiss R.S. The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis // Curr. Atheroscler. Rep. 2007. Vol. 9, N 4. P. 261-265.Sniderman A.D., Kiss R.S. The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis // Curr. Atheroscler. Rep. 2007. Vol. 9, N 4. P. 261-265.Austin M.A., King M.C., Vranizan K.M. et al. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis // Am. J. Hum. Genet. 1988. Vol. 43, N 6. P. 838-846.Austin M.A., King M.C., Vranizan K.M. et al. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis // Am. J. Hum. Genet. 1988. Vol. 43, N 6. P. 838-846.Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity // J. Lipid Res. 2002. Vol. 43, N 9. P. 1363-1379.Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity // J. Lipid Res. 2002. Vol. 43, N 9. P. 1363-1379.Lamon-Fava S., Fisher E.C., Nelson M.E. et al. Effect of exercise and menstrual cycle status on plasma lipids, low density lipoprotein particle size, and apolipoproteins // J. Clin. Endocrinol. Metab. 1989. Vol. 68, N 1. P. 17-21.Lamon-Fava S., Fisher E.C., Nelson M.E. et al. Effect of exercise and menstrual cycle status on plasma lipids, low density lipoprotein particle size, and apolipoproteins // J. Clin. Endocrinol. Metab. 1989. Vol. 68, N 1. P. 17-21.Bioletto S., Golay A., Munger R. et al. Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects // Am. J. Clin. Nutr. 2000. Vol. 71, N 2. P. 443-449.Bioletto S., Golay A., Munger R. et al. Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects // Am. J. Clin. Nutr. 2000. Vol. 71, N 2. P. 443-449.McNamara J.R., Jenner J.L., Li Z. et al. Change in LDL particle size is associated with change in plasma triglyceride concentration // Arterioscler. Thromb. 1992. Vol. 12, N 11. P. 1284-1290.McNamara J.R., Jenner J.L., Li Z. et al. Change in LDL particle size is associated with change in plasma triglyceride concentration // Arterioscler. Thromb. 1992. Vol. 12, N 11. P. 1284-1290.Rainwater D.L. Lipoprotein correlates of LDL particle size // Atherosclerosis. 2000. Vol. 148, N 1. P. 151-158.Rainwater D.L. Lipoprotein correlates of LDL particle size // Atherosclerosis. 2000. Vol. 148, N 1. P. 151-158.Julius U., Dittrich M., Pietzsch J. Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance // Int. J. Clin. Pract. 2007. Vol. 61, N 11. P. 1798-1804.Julius U., Dittrich M., Pietzsch J. Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance // Int. J. Clin. Pract. 2007. Vol. 61, N 11. P. 1798-1804.

The authors declare that there are no conflicts of interest present.